Oxycodone Drugs Global Market Report 2026

Oxycodone is a powerful opioid analgesic medication primarily used to manage moderate to severe pain. It belongs to the class of drugs called opioid agonists, which target specific receptors in the brain and spinal cord to change the way pain is perceived. Oxycodone is an effective option for pain management when used correctly and under the guidance of a healthcare professional.

The primary types of oxycodone drugs are short-acting oxycodone and long-acting oxycodone. Short-acting oxycodone refers to drug formulations that provide rapid pain relief but have a shorter duration of effect, typically used for managing acute pain conditions such as post-surgical discomfort or injury-related pain. Oxycodone drugs are available in various dosage forms, including tablets, capsules, and injections, and are indicated for neuropathic pain, musculoskeletal pain, cancer pain, postoperative pain, and other conditions. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have affected the oxycodone drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized excipients used in controlled-release formulations. Hospital pharmacies and regulated prescription markets in North America and Europe are most impacted due to strict sourcing requirements. These pressures have led manufacturers to reassess supply chains and invest in local API production. At the same time, tariffs have encouraged domestic manufacturing and improved supply security for essential pain management drugs.

The oxycodone drugs market research report is one of a series of new reports from The Business Research Company that provides oxycodone drugs market statistics, including oxycodone drugs industry global market size, regional shares, competitors with a oxycodone drugs market share, detailed oxycodone drugs market segments, market trends and opportunities, and any further data you may need to thrive in the oxycodone drugs industry. This oxycodone drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oxycodone drugs market size has grown strongly in recent years. It will grow from $5.98 billion in 2025 to $6.38 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to high prevalence of moderate to severe pain conditions, widespread use of opioids in post operative care, strong hospital demand for injectable analgesics, established clinical efficacy of oxycodone, limited availability of alternative pain therapies.

The oxycodone drugs market size is expected to see strong growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to stricter opioid prescribing regulations, growth of controlled-release pain management, increasing cancer and chronic pain cases, expansion of pain management clinics, development of safer opioid formulations. Major trends in the forecast period include shift toward abuse-deterrent oxycodone formulations, rising use of extended-release pain management therapies, growing preference for hospital-based opioid administration, increasing emphasis on prescription monitoring and compliance, expansion of generic oxycodone products in regulated markets.

The increasing prevalence of orthopedic disorders is anticipated to drive the expansion of the oxycodone drug market in the coming years. Orthopedic disorders encompass conditions affecting the bones, joints, ligaments, tendons, and muscles, often leading to chronic pain, limited mobility, and long-term functional impairments. The rise in orthopedic conditions is influenced by factors such as an aging population, sedentary lifestyles, obesity, sports-related injuries, and occupational strain. Oxycodone drugs aid in effective pain management by alleviating acute and chronic orthopedic pain, including fractures, joint damage, and post-surgical recovery, through their interaction with pain receptors in the central nervous system. For example, in February 2024, according to Arthritis Australia, a non-profit organization based in Australia, it is projected that in 2025, approximately 212,136 males and 362,137 females will have rheumatoid arthritis (RA), with these figures expected to increase by 2040 to around 280,040 males and 479,828 females. Consequently, the growing burden of orthopedic disorders is contributing to the expansion of the oxycodone drug market.

Major companies in the oxycodone drug market are focusing on the development of advanced abuse-deterrent immediate-release (IR) formulations to lower the risk of misuse through injection and intranasal administration. Abuse-deterrent IR opioids use physical and chemical barriers that make tablets challenging to crush, dissolve, or manipulate for non-oral routes, thereby improving patient safety and reducing diversion. For example, in October 2024, Protega Pharmaceuticals LLC, a US-based pharmaceutical company, obtained FDA approval for ROXYBOND(TM) (oxycodone hydrochloride) 10 mg immediate-release tablets featuring patented SentryBond abuse-deterrent technology. This technology is designed to resist physical manipulation and chemical extraction, making the tablets difficult to cut, crush, or dissolve for misuse via intranasal or intravenous routes. Consequently, it decreases the potential for abuse while still providing effective immediate-release pain relief for p

In February 2023, UNC Kenan-Flagler Business School, a US-based university for the Business of Health (CBOH), collaborated with Acadia Healthcare to create a flexible opioid settlement playbook. This collaboration seeks to direct communities toward the best methods for deploying opioid settlement funds, particularly as various U.S. communities, including those in North Carolina, obtain substantial resources to aid opioid recovery initiatives from lawsuits against opioid manufacturers and pharmacy chains. Acadia Healthcare Company Inc. is a US-based provider of behavioral healthcare services.

Major companies operating in the oxycodone drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Purdue Pharma L.P, Endo International plc, Amneal Pharmaceuticals LLC, Mundipharma Pty Limited, Alkermes plc, Mallinckrodt Pharmaceuticals, Alvogen Group Inc., Collegium Pharmaceutical Inc., Lannett Company Inc., Acorda Therapeutics Inc., Camurus AB, Rhodes Pharmaceuticals L.P., KVK Tech Inc., Teikoku Pharma USA Inc., Manus Aktteva Biopharma LLP, Zyla Life Sciences

North America was the largest region in the oxycodone drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxycodone drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oxycodone drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oxycodone drugs market consists of sales of codeine, morphine, hydrocodone, fentanyl, and methadone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oxycodone Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oxycodone drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oxycodone drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oxycodone drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Short Acting Oxycodone; Long Acting Oxycodone
• 2) By Dosage Form: Tablets; Capsules; Injections
• 3) By Indication: Neuropathic Pain; Musculoskeletal Pain; Cancer Pain; Post Operative Pain; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Short Acting Oxycodone: Immediate-Release Oxycodone Tablets; Oxycodone Oral Solution
• 2) By Long Acting Oxycodone: Extended-Release Oxycodone Tablets; Oxycodone Controlled-Release Formulations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Ltd; Purdue Pharma L.P; Endo International plc; Amneal Pharmaceuticals LLC; Mundipharma Pty Limited; Alkermes plc; Mallinckrodt Pharmaceuticals; Alvogen Group Inc.; Collegium Pharmaceutical Inc.; Lannett Company Inc.; Acorda Therapeutics Inc.; Camurus AB; Rhodes Pharmaceuticals L.P.; KVK Tech Inc.; Teikoku Pharma USA Inc.; Manus Aktteva Biopharma LLP; Zyla Life Sciences
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.